Bob Hoban – Forbes: McConnell’s Hemp Ban & The Schedule III Mirage: A Lesson In Cannabis Industry Myopia

DEA and FDA regulatory rules for Schedule III substances are neither simple nor immediate. While rescheduling may theoretically permit research, interstate commerce, and pharmaceutical-grade oversight, the existing regulations remain in place, and new rules would take years to develop, if they are ever developed. We know the existing Schedule II framework…because it already exists; nothing […]